Background: In vitro fertilization for women with polycystic ovarian syndrome is an essential (PCOS). New
methods to improve clinical outcomes are still needed. Objective: this research investigated the effectiveness of
PPOS and compared it with the standard PCOS antagonist regimen. Materials and procedures: A total of 76 PCOS
women eligible for aided therapy of reproductive technology were recruited in this RCT from February 2020 to May
2021 and put in random two groups (n=38/per group). Since the sixth day of the cycle, the PPOS group has received
20 mg/day orally of Dydrogesterone, while the control group received antagonist treatment. In addition to safety, our
results were chemical and clinical pregnancy. Results: oocyte retrieval counts, oocyte metaphase II (MII) and MI
have been comparable. There are also comparable numbers of fertilized oocytes and cleaved embryos without any
statistical difference in the number of injected oocytes. Lower antagonistic gonadotropin dosage than the PPOS group
(2957.8±301.9 vs 3197.4±545.9), with higher stimulation times respectively in the PPOS group than the antagonist.
Similar findings across both main outcome groups (OHSS) with no instances of FPPOS and just one case (2.6
percent) of moderate OHSS antagonists. Similar findings also for secondary results (biochemical pregnancy rate ,
clinical pregnancy rate and miscarriage rate). Conclusion: the established In PCOS patients receiving IVF/ICSI
therapy, PPOS is a safe and successful procedure.
|
